Health Technology Assessment (hta) & Pra Lead, Ksa

Eli Lilly Eli Lilly · Pharma · Saudi Arabia

This role focuses on Health Technology Assessment (HTA) and Pricing, Reimbursement & Access (PRA) within the Saudi Arabian healthcare market. The Lead will develop economic models, evidence packages, and HTA content for payer submissions, and design/deliver training programs for PRA and Key Account Management (KAM) teams to improve their economic fluency and payer engagement. The goal is to accelerate access for Lilly's innovations and sustain access for existing products in a maturing reimbursement environment.

What you'd actually do

  1. Partner closely with the PRA Leads and Market Access to provide the economic tools, models, and HTA evidence required to execute the affiliate's payer and access strategy across Lilly's KSA portfolio.
  2. Develop, adapt, and validate health economic models — cost-effectiveness, budget impact, and cost-consequence analyses — tailored to the Saudi healthcare context, with robust local epidemiological, cost, and clinical assumptions.
  3. Produce the economic content and HTA components of payer submissions to SFDA, and public sector and reimbursement institutions, and other relevant payers — under the strategic direction of the PRA Leads, who own access and reimbursement outcomes.
  4. Design and deliver a comprehensive capability-building program for the Saudi PRA function and the KAM team, covering HTA fundamentals, health economics, payer archetypes, value communication, account planning, and negotiation.
  5. Serve as the affiliate's subject-matter expert on HTA and health economics, providing the technical economic insight that informs the PRA Director's, PRA Leads', and brand teams' access strategy and value evidence decisions.

Skills

Required

  • Health Technology Assessment (HTA)
  • Health Economics
  • Economic modeling (cost-effectiveness, budget impact, cost-consequence)
  • Payer engagement
  • Saudi healthcare market knowledge
  • Regulatory submissions (SFDA)
  • Capability building/training design

Nice to have

  • Real-world evidence (RWE) integration
  • Innovative pricing constructs (managed entry agreements, outcomes-based, risk-share)
  • Scientific committee engagement
  • ISPOR experience

What the JD emphasized

  • HTA
  • economic models
  • payer submissions
  • value-based reimbursement
  • Saudi healthcare context
  • SFDA